Inhibiting RIPK1 kinase activity ameliorates the defects of microglial phagocytosis and the production of neurotoxic cytokines during neurodegeneration, while it remains largely unknown what causes or modulates the activation of RIPK1 in neurodegenerative diseases. Here, RIPK1 is linked to neurodegenerative disease.